Rhumbline Advisers lifted its stake in Cambrex Co. (NYSE:CBM) by 15.5% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 75,657 shares of the biotechnology company’s stock after buying an additional 10,177 shares during the quarter. Rhumbline Advisers owned about 0.23% of Cambrex worth $3,632,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Aperio Group LLC raised its stake in shares of Cambrex by 10.5% in the fourth quarter. Aperio Group LLC now owns 9,759 shares of the biotechnology company’s stock worth $468,000 after buying an additional 927 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Cambrex by 117.0% in the third quarter. JPMorgan Chase & Co. now owns 231,931 shares of the biotechnology company’s stock worth $12,721,000 after buying an additional 125,062 shares during the period. Granite Investment Partners LLC raised its stake in shares of Cambrex by 6.3% in the third quarter. Granite Investment Partners LLC now owns 243,710 shares of the biotechnology company’s stock worth $13,405,000 after buying an additional 14,366 shares during the period. Envestnet Asset Management Inc. raised its stake in shares of Cambrex by 37.5% in the third quarter. Envestnet Asset Management Inc. now owns 17,623 shares of the biotechnology company’s stock worth $968,000 after buying an additional 4,803 shares during the period. Finally, Algert Global LLC bought a new position in shares of Cambrex in the fourth quarter worth about $343,000.
Several research analysts have recently commented on CBM shares. William Blair started coverage on Cambrex in a research note on Tuesday, January 16th. They issued an “outperform” rating on the stock. Longbow Research downgraded Cambrex from a “buy” rating to a “neutral” rating in a research note on Wednesday, February 14th. Finally, Zacks Investment Research raised Cambrex from a “strong sell” rating to a “hold” rating in a research note on Monday, January 15th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $60.00.
Cambrex Co. (NYSE:CBM) opened at $55.15 on Thursday. The firm has a market capitalization of $1,844.35, a P/E ratio of 17.22, a price-to-earnings-growth ratio of 1.36 and a beta of 2.38. Cambrex Co. has a 1-year low of $42.55 and a 1-year high of $62.95.
Cambrex (NYSE:CBM) last released its quarterly earnings results on Thursday, February 8th. The biotechnology company reported $1.27 earnings per share for the quarter, beating the consensus estimate of $1.10 by $0.17. The business had revenue of $182.28 million during the quarter, compared to analysts’ expectations of $181.39 million. Cambrex had a return on equity of 22.42% and a net margin of 19.17%. The firm’s revenue for the quarter was up 2.5% compared to the same quarter last year. During the same quarter last year, the business posted $1.23 EPS. analysts forecast that Cambrex Co. will post 2.76 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Rhumbline Advisers Increases Holdings in Cambrex Co. (CBM)” was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://ledgergazette.com/2018/03/15/rhumbline-advisers-increases-holdings-in-cambrex-co-cbm.html.
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Co. (NYSE:CBM).
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.